Adjunct Faculty
Adjunct faculty typically have an academic or research appointment at another institution and contribute or collaborate with one or more School of Medicine faculty members or programs.
Adjunct rank detailsBrittany Craiglow, MD
Associate Professor Adjunct - DermatologyAbout
Research
Publications
2026
084 Baricitinib Provides Higher Efficacy in Adolescents Relative to Adults With Alopecia Areata Despite More Severe Disease at Baseline: 36-Week Outcomes From BRAVE-AA Trials
Passeron T, Arkin L, Ohyama M, Vleugels R, Senna M, Dutronc Y, Das T, Sontag A, Somani N, Craiglow B. 084 Baricitinib Provides Higher Efficacy in Adolescents Relative to Adults With Alopecia Areata Despite More Severe Disease at Baseline: 36-Week Outcomes From BRAVE-AA Trials. Journal Of Investigative Dermatology 2026, 146: s20. DOI: 10.1016/s0022-202x(26)00617-2.Peer-Reviewed Original ResearchPhase 3 trialSALT scoreAlopecia areataSevere AAPrimary endpointSevere alopecia areataJanus kinase inhibitorsBenefits of early interventionPediatric subjectsKinase inhibitorsSevere diseaseResponse ratePatientsBL characteristicsPlaceboCharacteristics of adolescentsAreataBaricitinibEarly interventionBaselineEndpointAdolescentsEfficacyAdultsDiseaseHeterozygous variants in DOCK2 leading to susceptibility to viral illnesses
Al-Musa A, Platt C, Elkins M, Novak T, Woods B, Bourdine A, Magin L, Craiglow B, Newhams M, Kong M, Randolph A, Chou J. Heterozygous variants in DOCK2 leading to susceptibility to viral illnesses. The Journal Of Allergy And Clinical Immunology 2026 PMID: 41654261, PMCID: PMC13016768, DOI: 10.1016/j.jaci.2026.01.026.Peer-Reviewed Original ResearchInborn errors of immunityErrors of immunityHeterozygous variantsInborn errorsHealthy individualsIFN-a therapyAntiviral immunitySoft tissue infectionsHuman papilloma virusHeterozygous pathogenic variantsCohort of patientsImpaired antiviral immunityRespiratory syncytial virusToll-like receptor signalingAged 3 monthsAutosomal-recessive diseaseSusceptibility to infectionRefractory wartsRecurrent infectionsPapilloma virusDOCK2 deficiencySyncytial virusSevere acute respiratory syndrome coronavirus 2Severe infectionsViral illness
2025
Successful Treatment of Alopecia Areata With One JAK Inhibitor After Failure of Other JAK Inhibitors
Kalil L, Craiglow B, King B. Successful Treatment of Alopecia Areata With One JAK Inhibitor After Failure of Other JAK Inhibitors. JAMA Dermatology 2025, 161: 1285-1287. PMID: 41060634, PMCID: PMC12509074, DOI: 10.1001/jamadermatol.2025.3537.Peer-Reviewed Original ResearchBaricitinib Provides Higher Efficacy in Adolescents Relative to Adults With Alopecia Areata Despite More Severe Disease at Baseline: 36-Week Outcomes From BRAVE-AA Trials
Passeron T, Arkin L, Ohyama M, Vleugels R, Senna M, Dutronc Y, Chestnut Colvin S, Das T, Sontag A, Somani N, Craiglow B. Baricitinib Provides Higher Efficacy in Adolescents Relative to Adults With Alopecia Areata Despite More Severe Disease at Baseline: 36-Week Outcomes From BRAVE-AA Trials. SKIN The Journal Of Cutaneous Medicine 2025, 9: s660. DOI: 10.25251/1g590e41.Peer-Reviewed Original ResearchPhase 3 trialSALT scoreAlopecia areataSevere AAPrimary endpointSevere alopecia areataJanus kinase inhibitorsBenefits of early interventionPediatric subjectsKinase inhibitorsSevere diseaseResponse ratePatientsBL characteristicsPlaceboCharacteristics of adolescentsAreataBaricitinibEarly interventionBaselineEndpointAdolescentsEfficacyAdultsDiseaseDiscontinuation and restart of Janus kinase inhibitors due to pregnancy in alopecia areata: a case series
Ogbutor C, Chen L, Kalil L, Kelley K, Craiglow B, King B, Senna M. Discontinuation and restart of Janus kinase inhibitors due to pregnancy in alopecia areata: a case series. International Journal Of Women's Dermatology 2025, 11: e218. PMID: 40810112, PMCID: PMC12348381, DOI: 10.1097/jw9.0000000000000218.Peer-Reviewed Original ResearchTreatment of Short Anagen Syndrome With Low‐Dose Oral Minoxidil
Francis N, Craiglow B. Treatment of Short Anagen Syndrome With Low‐Dose Oral Minoxidil. Pediatric Dermatology 2025, 43: 220-221. PMID: 41001993, DOI: 10.1111/pde.70049.Peer-Reviewed Original Research65063 Characterization of treatment, disease burden, and patient-reported outcome measures in a real-world cohort of patients with alopecia areata: the CorEvitas Alopecia Areata Registry
Senna M, Craiglow B, Malley W, Wahl P, McLean R, King B. 65063 Characterization of treatment, disease burden, and patient-reported outcome measures in a real-world cohort of patients with alopecia areata: the CorEvitas Alopecia Areata Registry. Journal Of The American Academy Of Dermatology 2025, 93: ab144. DOI: 10.1016/j.jaad.2025.05.576.Peer-Reviewed Original Research61346 Baseline Psychosocial Impact of Disease in Patients with Severe Alopecia Areata Treated with Baricitinib Recruited from the US Customer Support Program
Mostaghimi A, Mayo T, Craiglow B, Goh C, Murage M, Ball S, Dabbous F, Kawata A, Somani N, Tosti A. 61346 Baseline Psychosocial Impact of Disease in Patients with Severe Alopecia Areata Treated with Baricitinib Recruited from the US Customer Support Program. Journal Of The American Academy Of Dermatology 2025, 93: ab132. DOI: 10.1016/j.jaad.2025.05.531.Peer-Reviewed Original Research62923 Patient Preferences for the Treatment of Alopecia Areata
Craiglow B, Senna M, Mesinkovska N, Harshaw Q, Deering K, Shaikh A, Barghout V, Cassella J, Ferro T. 62923 Patient Preferences for the Treatment of Alopecia Areata. Journal Of The American Academy Of Dermatology 2025, 93: ab68. DOI: 10.1016/j.jaad.2025.05.274.Peer-Reviewed Original ResearchStatement from the frontal fibrosing alopecia international expert alliance: SOFFIA 2024
Meah N, Li J, Wall D, York K, Bhoyrul B, Bokhari L, Coulthard L, Asfour L, Abraham L, Asz‐Sigall D, Bergfeld W, Betz R, Blume‐Peytavi U, Callender V, Chitreddy V, Combalia A, Cotsarelis G, Craiglow B, Dhurat R, Dlova N, Donovan J, Doroshkevich A, Eisman S, Farrant P, Gadzhigoroeva A, Green J, Grimalt R, Harries M, Hordinsky M, Irvine A, Jolliffe V, Kaiumov S, King B, Kossard S, Lee J, Lee W, Lortkipanidze N, McMichael A, Mesinkovska N, Messenger A, Mirmirani P, Olsen E, Orlow S, Ovcharenko Y, Piraccini B, Pirmez R, Rakowska A, Reygagne P, Roberts J, Rudnicka L, Saceda‐Corralo D, Shapiro J, Sharma P, Silyuk T, Suchonwanit P, Takwale A, Tosti A, Visser W, Vañó‐Galván S, Vogt A, Wade M, Yip L, Zlotogorski A, Zhou C, Sinclair R. Statement from the frontal fibrosing alopecia international expert alliance: SOFFIA 2024. Journal Of The European Academy Of Dermatology And Venereology 2025, 40: 210-223. PMID: 40698981, PMCID: PMC12843854, DOI: 10.1111/jdv.20833.Peer-Reviewed Original ResearchFrontal fibrosing alopeciaPrognostic indicatorIncidence of frontal fibrosing alopeciaOptimal treatment algorithmEvidence-based treatment recommendationsThree-round Delphi processInternational consensus statementSystemic therapyTreatment algorithmTreatment modalitiesPhysical therapyTreatment recommendationsConsensus statementDelphi processRobust researchExpert consensusConsensus thresholdDisease monitoringConsensus agreementTherapy